Celldex reiterated as a Focus Pick at Roth Capital Roth Capital reiterated Celldex as its Focus Pick citing its broad pipeline and the potential for accelerated approval for either ORR or PFS. Shares are Buy rated with a $16 price target.
Celldex appoints Richard Wright as Chief Commercial Officer Celldex Therapeutics announced the promotion of Richard Wright, Ph.D. to SVP and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.